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Abstract
Introduction:  Phenotypic  overlap  between  the  two  main  chronic  airway  pulmonary  diseases,
asthma and  chronic  obstructive  pulmonary  disease  (COPD),  has  been  the  subject  of  debate  for
decades, and  recently  the  nomenclature  of  asthma-COPD  overlap  syndrome  (ACOS)  was  adopted
for this  condition.  The  definition  of  this  entity  in  the  literature  is,  however,  very  heterogeneous,
it is  therefore  important  to  define  how  it  applies  to  Portugal.
Methods:  A  literature  review  of  ACOS  was  made  in  a  first  phase  resulting  in  the  drawing  up
of a  document  that  was  later  submitted  for  discussion  among  a  panel  of  chronic  lung  dis-
eases experts,  resulting  in  reflexions  about  diagnosis,  treatment  and  clinical  guidance  for  ACOS
patients.
Abbreviations: ACOS, asthma-COPD overlap syndrome; BD, bronchodilation; CARAT, control of allergic rhinitis and asthma test; COPD,
chronic obstructive pulmonary disease; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; GINA, Global Initiative for Asthma; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; IgE,
immunoglobulin E; IL, interleukin; LABA, long acting beta agonist; LAMA, long acting muscarinic antagonist; LLN, lower limit of normal;
mMRC scale, modified Medical Research Council scale; PEF, peak expiratory flow; RCT, randomized controlled trial; 6MWT, 6-min walking
test.Please  cite  this  article  in  press  as:  Araújo  D,  et  al.  Rev  Port  Pneumol.  2016.
http://dx.doi.org/10.1016/j.rppnen.2016.11.005
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Results:  There  was  a  consensus  among  the  experts  that  the  diagnosis  of  ACOS  should  be  consid-
ered in  the  concomitant  presence  of:  clinical  manifestations  characteristic  of  both  asthma  and
COPD, persistent  airway  obstruction  (post-bronchodilator  FEV1/FVC  <  0.7),  positive  response
to bronchodilator  test  (increase  in  FEV1 of  ≥200  mL  and  ≥12%  from  baseline)  and  current  or
past history  of  smoking  or  biomass  exposure.  In  reaching  diagnosis,  the  presence  of  peripheral
eosinophilia  (>300  eosinophils/L  or  >5%  of  leukocytes)  and  previous  history  of  atopy  should  also
be considered.  The  recommended  first  line  pharmacological  treatment  in  these  patients  is  the
ICS/LABA  association;  if  symptomatic  control  is  not  achieved  or  in  case  of  clinical  severity,  triple
therapy with  ICS/LABA/LAMA  may  be  used.  An  effective  control  of  the  exposure  to  risk  factors,
vaccination,  respiratory  rehabilitation  and  treatment  of  comorbidities  is  also  important.
Conclusions:  The  creation  of  initial  guidelines  on  ACOS,  which  can  be  applied  in  the  Portuguese
context,  has  an  important  role  in  the  generation  of  a  broad  nationwide  consensus.  This  will
give, in  the  near  future,  a  far  better  clinical,  functional  and  epidemiological  characterization
of ACOS  patients,  with  the  ultimate  goal  of  achieving  better  therapeutic  guidance.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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sthma  and  COPD  are  chronic  lung  diseases  which  are  highly
revalent  and  have  significant  socio-economic  impact.1,2
ata  from  a  recent  nationwide  study  indicate  that  the  cur-
ent  asthma  prevalence  in  the  Portuguese  population  is
.8%.3 The  national  prevalence  for  COPD  was  estimated  in
.0%  and  5.3%  in  2  previous  studies  --  in  selected  age  groups
≥40  years  old  in  one  study  and  between  35  and  69  years
ld  in  the  other);  there  is  also  another  study  carried  out
n  the  Lisbon  area  that  showed  a  prevalence  of  14.2%  (in
atients  of  40  years  old  or  more).4,5 Both  asthma  and  COPD
ffect  the  airways  and  are  characterized  by  the  presence
f  bronchial  obstruction.1,2 Even  though  these  pathologies
re  heterogeneous,  they  usually  present  quite  character-
stic  clinical  symptoms,  functional  changes  and  underlying
hysiopathology,  which  enables  a  straightforward  diagnosis
n  a  majority  of  patients.1,2,6 However,  there  is  a grow-
ng  consensus  that  typical  asthma  and  COPD  characteristics
an  both  exist  simultaneously  in  one  patient,  especially
n  those  who  are  older  and  have  a  history  of  smoking.6--8
ata  from  the  INAsma  study  clearly  show  that,  in  Portugal,
sthmatic  patients  smoke  in  the  same  proportion  as  the  non-
sthmatic  and  that  the  passive  exposure  is  even  higher  in
he  first  group.9 In  reality,  there  are  patients  with  severe
sthma,  that  has  evolved  over  a  long  period  and  frequently
ith  smoking  habits,  that  eventually  develop  fixed  airway
bstruction,  a  pattern  usually  seen  in  COPD.10,11 On  the  other
and,  a  positive  bronchodilator  test,  as  seen  in  many  asthma
atients,  can  be  found  in  a  significant  proportion  of  COPD
atients,  although  not  of  same  magnitude.12,13 In  this  con-
ext,  the  concept  of  ACOS  (asthma-COPD  overlap  syndrome)
as  been  used  to  describe  this  set  of  patients  that  present
oncomitant  asthma  and  COPD  characteristics.  It  is  impor-
ant  to  highlight  that  in  this  group  of  patients,  although  they
how  a  broad  clinical  heterogeneity,  there  are  essentiallyPlease  cite  this  article  in  press  as:  Araúj
http://dx.doi.org/10.1016/j.rppnen.2016.11.005
wo  types  of  patients:  the  asthmatic  patient  that  develops
COS  and  the  COPD  patient  that  presents  clinical  charac-
eristics  of  ACOS.  It  is,  thus,  important  to  be  aware  that
n  these  cases  there  is  an  initial  distinct  physiological  base
p
w
w
that  culminates  in  an  overlap  of  symptoms,  which  can  have
mplications  for  diagnosis  and  therapy.
The  way  these  patients  are  characterized  by  the  several
ntities  analysing  this  issue  is  very  heterogeneous,  which
akes  it  difficult  to  apply  the  concept  of  ACOS  to  the  clini-
al  situation  in  Portugal.  In  this  context,  there  is  a  need  for
 first  step  towards  clarification  of  concepts  applied  to  the
ational  context,  in  order  to  develop,  in  the  near  future,  a
roader  ACOS  medical  consensus.  This  paper  is  an  indexed
iterature  revision  on  the  subject,  complemented  by  a  series
f  critical  reflexions  regarding  diagnostic  criteria,  patient
dentification,  therapeutic  approaches  and  guidelines  for
uture  clinical  investigation.
ethods
 literature  review  was  carried  out  via  the  PubMed  database
y  searching  for  MeSH  Terms  (‘‘asthma’’,  ‘‘chronic  obstruc-
ive  lung  disease’’,  ‘‘overlap  syndrome’’).  Articles  between
006  and  2016  were  selected  as  relevant  if  they  had  epi-
emiological  data,  diagnostic  criteria,  clinical  symptoms
nd  impact  and  therapeutic  approaches.  In  a  second  phase,
 working  meeting  was  held  with  medical  experts  from  the
hronic  lung  diseases  field  (Pulmonology,  Immunoallergol-
gy,  Family  Medicine)  where  the  several  topics  presented
n  this  paper  were  discussed  and  proposals  for  recom-
endations  on  ACOS  adapted  to  the  Portuguese  context
rawn  up.
linical characterization and impact
he  differentiation  in  terms  of  respiratory  symptoms
etween  asthma  and  COPD  is,  in  many  cases,  quite  difficult,
ecause  there  are  several  areas  where  they  can  overlap,
aking  the  distinction  more  complicated.  For  example,  theo  D,  et  al.  Rev  Port  Pneumol.  2016.
resence  of  chronic  productive  cough  is  more  associated
ith  COPD  but  can  also  be  present  in  an  asthmatic  patient,
hich  leads  to  a  worse  prognosis  in  terms  of  pulmonary  func-
ion  decline.14 On  the  other  hand,  it  is  also  common  to  have
 IN+Model
rome
s
h
r
s
m
D
C
T
p
t
s
c
a
S
T
p
p
T
c
t
a
t
t
a
s
u
a
c
c
c
4
e
(
w
(
≥
s
S
A
a
n
n
o
d
hARTICLERPPNEN-1205; No. of Pages 10
Asthma-chronic  obstructive  pulmonary  disease  overlap  synd
the  presence  of  asthmatic  symptoms  (occasional  dyspnoea,
sibilance)  in  COPD  patients.15 In  terms  of  bronchodilator
response,  the  reversibility  seen,  although  typical  in  asthma,
is  not  exclusive  to  it,  as  it  is  also  observed  in  up  to  50%  of
COPD  patients.16 Furthermore,  the  bronchial  hyperrespon-
siveness,  which  is  present  in  almost  all  asthma  patients,  can
also  be  seen  in  a  significant  percentage  of  COPD  cases.17
This  clinical  diversity  leads  to  the  overlap  between  these
two  obstructive  respiratory  diseases.  It  is  possible,  how-
ever,  to  isolate  characteristics  that  enable  the  recognition
of  a  new  entity  (ACOS)  which  aggregates  features  from  both
(asthma  and  COPD).
Several  studies  have  analyzed  the  clinical  differences
between  ACOS,  COPD  and  asthma,  showing  a  higher  preva-
lence  of  respiratory  symptoms  in  patients  with  ACOS
compared  to  the  other  two  alone.18,19 In  the  ACOS
group,  studies  show  a  more  significant  exertional  dyspnoea
(assessed  by  the  mMRC  score),20 a  higher  percentage  of  sibi-
lance  when  compared  with  COPD  patients,21 less  physical
capacity,  more  exacerbations  and  lower  quality  of  life.22 In
the  population-based  study  (EPI-SCAN21)  the  authors  com-
pared  the  prevalence  of  symptoms  between  COPD,  asthma
and  ACOS  patients,  observing  a  higher  percentage  of  dysp-
noea  in  the  ACOS  group,  more  sibilance  in  the  ACOS  group
when  compared  to  the  COPD  group,  and  an  equal  percentage
of  productive  cough  in  COPD  and  ACOS.  Two  other  studies
(GEIRD  and  PLATINO18,22)  revealed,  however,  a  higher  per-
centage  of  productive  cough  in  ACOS  patients,  even  when
compared  to  isolated  cases  of  COPD.
On  the  other  hand,  the  exercise  capacity  shown  by  ACOS
patients  was  prospectively  analyzed  by  Fu  et  al.  in  a  4-
year  follow-up  study  which  concluded  that  the  functional
decrease  in  terms  of  6-min  walk  test  (6MWT)  was  lower  in
these  patients  compared  to  the  COPD  group.23
There  is  no  consensus  on  the  results  concerning  lung  func-
tion,  although  many  studies  show  lower  values  of  FEV1, FVC
and  FEV1/FVC  in  patients  with  ACOS  compared  to  COPD  and
asthma.18,24 Other  studies  reveal  that  there  are  no  signifi-
cant  differences  between  these  groups  in  this  area.23,25,26
In  relation  to  radiological  differences  between  ACOS  and
COPD,  there  seems  to  be  a  slightly  less  emphysema  expres-
sion  in  the  first  group  as  well  as  a  predilection  for  the  upper
lung  lobes.27
There  is  a  higher  degree  of  consensus  between  the
studies  over  exacerbations,  with  a  higher  rate  in  ACOS
patients.18,19,21 There  is  also  a  higher  percentage  of  severe
exacerbations  and  a  higher  rate  of  hospitalizations.  In  a
study  performed  by  Brzostek  and  Kokot  a  significant  rate  of
recent  exacerbations  (69%  in  the  last  year)  was  observed.28
In  terms  of  comorbidities,  studies  point  towards  a  high
prevalence  in  ACOS,  especially  cardiovascular  ones.  Some
authors  have  referred  to  a  higher  incidence  in  ACOS  patients
compared  to  COPD  and  asthma  but  that  is  not  applicable
to  the  whole  literature.20,24,28 Miravittles  et  al.  have  used
the  Charlson  Comorbidity  Index  as  a  mortality  prognos-
tic  indicator,  showing  a  significantly  higher  value  in  ACOS
patients.21
Chronic  obstructive  pulmonary  diseases,  due  to  its  preva-Please  cite  this  article  in  press  as:  Araúj
http://dx.doi.org/10.1016/j.rppnen.2016.11.005
lence  and  health-resource  consumption  needs,  have  a  higher
economic  burden  associated  with  them.  Within  these,  COPD
has  clearly  more  burdensome  than  asthma.29 However,  a
cost  comparative  analysis  between  ACOS  and  COPD,  clearly
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hows  a  higher  value  for  the  former,  mainly  because  of  the
igher  rate  of  hospital  admission.30
The  ACOS-associated  mortality  rate  was  addressed  in  a
ecent  analysis  of  a  multicentric  Italian  study  (SARA  study),31
howing  no  significant  differences  compared  to  COPD  but
uch  higher  than  asthma.
iagnostic criteria/biomarkers
linical  criteria
he  identification  of  patients  with  ACOS  in  daily  clinical
ractice  is  based,  in  a  first  phase,  on  the  recognition  of  cer-
ain  clinical  features  of  both  asthma  and  COPD  being  present
imultaneously  in  the  same  patient,  as  previously  stated.6,7
Proposed  recommendation:  simultaneous  presence  of
linical  features  of  asthma  and  COPD  should  be  considered
s  a  criterion  for  the  diagnosis  of  ACOS.
pirometric  criteria
he  presence  of  persistent  airflow  limitation,  defined  as
ost-bronchodilator  FEV1/FVC  <  0.7,  is  one  of  the  criteria
roposed  by  several  authors  for  the  diagnosis  of  ACOS.18,32,33
he  fixed  cut-off  value  of  this  ratio,  although  an  essential
riterion  for  the  diagnosis  of  COPD,  does  not  help,  however,
he  differentiation  between  asthma  and  COPD.2,6
A  positive  response  to  the  bronchodilator  test,  usually
ssociated  with  asthma  diagnosis,  can  also  be  found  in  cer-
ain  patients  with  COPD.1,16,34 In  these,  this  response  tends
o  present  a  lower  magnitude,  may  be  inconsistent  over  time
nd  does  not  necessarily  reflect  the  presence  of  overlap
yndrome.16,34,35 However,  since  there  are  certain  individ-
als  who  only  manifest  the  first  symptoms  of  asthma  in
dulthood,  the  presence  of  a  positive  response  to  bron-
hodilator  test  is  also  frequently  assumed  to  be  an  agreed
riterion  to  be  considered  for  the  diagnosis  of  ACOS,  espe-
ially  if  it  is  a very  positive  response  (increase  of  15%  and
00  mL  in  FEV1).36,37
Proposed  recommendation:  there  was  consensus  among
xperts  that  the  presence  of  persistent  airway  obstruction
defined  as  post-bronchodilator  FEV1/FVC  <  0.7)  associated
ith  evidence  of  a  positive  response  in  bronchodilator  test
defined  as  an  increase  in  the  value  of  FEV1 of  ≥200  mL  and
12%  from  baseline)  at  least  in  one  functional  evaluation
hould  be  a  criterion  for  the  diagnosis  of  ACOS.
ystemic  and  airway  inflammation
irway  inflammation  is  a  common  feature  of  asthma
nd  COPD;  in  many  asthma  phenotypes  it  is  predomi-
antly  eosinophilic,  while  in  COPD  there  is  a  predominant
eutrophilia.38 However,  in  asthmatic  smokers  or  in  severe
r  late-onset  asthma,  a  neutrophilic  inflammation  has  been
emonstrated,  which  is  similar  to  COPD.38,39 On  the  other
and,  peripheral  or  sputum  eosinophilia,  as  well  as  theo  D,  et  al.  Rev  Port  Pneumol.  2016.
levation  of  the  fractional  exhaled  nitric  oxide  (FENO)
nd  immunoglobulin  E  (IgE),  although  generally  more  often
bserved  in  asthmatic  patients,  have  also  been  demon-
trated  in  certain  patients  with  COPD.1,40--43 In  addition,
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 higher  peripheral  and  sputum  eosinophilia  have  been
ound  in  patients  with  COPD  and  partial  reversibility  of
irflow  limitation44;  it  was  further  observed  that  the  pres-
nce  of  eosinophilia  in  the  sputum  of  COPD  patients
as  been  associated  with  a  better  response  to  treatment
ith  inhaled  corticosteroids.16 It  is  further  noted  that,  in
sthma,  the  presence  of  sputum  eosinophilia  is  a  factor  that
an  be  determinant  for  the  development  of  fixed  airway
bstruction.45 Thus,  the  applicability  of  these  markers  has
een  subject  of  study  to  support  the  diagnosis  of  ACOS.43,46
The  identification  of  other  systemic  inflammation
iomarkers  that  aid  the  diagnosis  and  help  towards  a  better
lassification  of  patients  with  obstructive  airway  diseases
as  been  investigated.  Although  several  markers  have  been
uggested,  such  as  interleukin-6  (IL-6),  periostin,  C-reactive
rotein,  among  others,  none  of  these  has  been,  to  date,
ncluded  as  diagnostic  criteria,  given  the  lack  of  evidence
o  support  their  applicability,  since  their  role  has  not  been
et  completely  determined.47--49
Proposed  recommendation:  peripheral  eosinophilia
defined  by  the  presence  of  >300  eosinophils/L or  >5%
f  the  leukocytes)  and  elevation  of  IgE  are  aspects  fre-
uently  found  in  this  group  of  patients,  and  should  be  taken
nto  account  when  considering  the  diagnosis,  although  they
annot  be  used  as  main  diagnostic  criteria.  Since  the  deter-
ination  of  sputum  eosinophilia  is  a  method  that  is  not
idely  available  in  Portugal  and  the  determination  of  FENO
as  fallen  into  disuse,  we  did  not  consider  recommending
heir  inclusion  as  diagnostic  criteria  which  could  be  used  in
linical  practice.  There  is  no  scientific  evidence  enough  to
upport  its  use.  There  is  not  enough  scientific  evidence  to
upport  the  use  of  other  potential  serum  biomarkers  in  this
ontext.
xposure  (tobacco  and  biomass  combustion)
moking  has  been  established  as  a  risk  factor  for  the  devel-
pment  of  COPD  and  it  accelerates  the  rate  of  lung  function
ecline  in  both  asthma  and  COPD.1,2,50 Additionally,  it  may
e  at  the  bottom  of  fixed  airway  obstruction  development  in
sthmatics.1,51 In  a  similar  way,  exposure  to  biomass  combus-
ion  is  also  associated  with  airway  obstruction.2,52 Thus,
current  or  past)  smoking  habits,  as  well  as  a  history  of  expo-
ure  to  biomass,  are  generally  included  as  criteria  for  the
iagnosis  of  ACOS.
Proposed  recommendation:  the  presence  of  current  or
ast  history  of  smoking  or  biomass  combustion  exposure
hould  be  considered  as  a  criterion  for  the  diagnosis  of  ACOS,
s  this  exposure  is  associated  with  the  development  and
everity  of  asthma  and  COPD.
istory  of  asthma  or  atopy  before  40  years  old
he  diagnosis  of  asthma  is  most  commonly  made  in  child-
ood,  but  sometimes  it  can  only  be  diagnosed  in  adulthood.1
dditionally,  asthma,  by  itself,  is  a  risk  factor  for  COPD
evelopment.53 On  the  other  hand,  atopy  is  assumed  to  bePlease  cite  this  article  in  press  as:  Araúj
http://dx.doi.org/10.1016/j.rppnen.2016.11.005
 risk  factor  commonly  associated  with  asthma,  but  can  also
e  found  in  a  significant  percentage  of  patients  with  COPD
nd  may  be  a  risk  factor  for  development  of  COPD.1,54--56
hus,  in  most  publications,  for  patients  diagnosed  with
m
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OPD,  these  criteria  have  been  taken  into  consideration  for
iagnosis  of  ACOS.
Proposed  recommendation:  the  presence  of  a  previous
istory  of  atopy  is  an  aspect  often  found  in  this  group  of
atients,  so  it  should  be  taken  into  account  when  considering
he  diagnosis,  although  it  cannot  be  assumed  as  a  diagnostic
riterion.  It  was  not  considered  important  to  establish  an
ge  limit  that  should  be  taken  into  account  or  applied  as  a
riterion.
ronchial  hyperresponsiveness
t  has  been  shown  that  the  presence  of  bronchial  hyperre-
ponsiveness,  even  though  it  may  be  found  asymptomatically
n  the  general  population,  is  associated  with  an  increased
isk  of  asthma  and  COPD,  and  might  in  both  cases  be  a
arker  of  more  severe,  more  symptomatic  disease  and  a
reater  decline  in  lung  function.57,58 In  fact,  bronchial  hyper-
esponsiveness,  present  in  virtually  all  asthmatic  patients,
ay  also  be  found  in  60--90%  of  patients  with  COPD,  and  in
hese  it  may  be  associated  with  more  symptoms  and  greater
everity  of  obstruction.17,59
Proposed  recommendation:  since  the  presence  of
ronchial  hyperresponsiveness  is  expected  in  asthmatic
atients  and  bearing  in  mind  that  it  can  be  detected  in
 very  high  proportion  of  COPD  patients,  the  presence  of
his  aspect,  which  has  a  low  specificity,  was  not  considered
elevant  for  the  diagnosis.
efinition
everal  study  groups  have  published  highly  diverse  pro-
osals  for  definitions  and  diagnostic  criteria  for  ACOS,
ost  of  these  recommendations  originating  from  expert
pinion  consensus.47,60--62 The  description  proposed  by  the
oint  project  of  GOLD  and  GINA  characterizes  ACOS  as
he  presence  of  persistent  airflow  limitation  with  several
haracteristics  usually  associated  with  asthma  and  several
haracteristics  usually  associated  with  COPD.6 This  defini-
ion  is  vague  and  the  diagnosis  is  based  on  the  balance  of
ttributes  taken  from  a  checklist  with  typical  asthma  and
OPD  aspects.
In  fact,  ACOS  is  still  poorly  characterized,  both  in  terms
f  general  risk  factors  and  pathophysiology,  and  in  terms  of
linical  symptoms,  treatment  response  and  prognosis.  This
s  largely  due  to  the  fact  that  patients  who  meet  criteria
ompatible  with  a  possible  diagnosis  of  ACOS  are  usually
xcluded  from  clinical  trials  targeting  COPD  or  asthma.
Table  1  summarizes  the  main  definitions  and  diagnostic
riteria  proposed  by  several  authors.
Therefore,  although  there  is  no  agreed,  established  and
alidated  definition  for  ACOS,  this  entity  is  widely  recog-
ized  in  clinical  practice  as  an  individualized  phenotype
emarcated  from  the  spectrum  of  chronic  obstructive  air-
ays  disease.67 In  addition,  the  identification/recognition
f  this  phenotype  of  chronic  obstructive  respiratory  diseaseo  D,  et  al.  Rev  Port  Pneumol.  2016.
ay  influence  the  prognostic  and  therapeutic  approach.
hus,  it  is  really  necessary  to  establish  a  consensus,  based  on
 review  of  the  available  literature  and  professional  expe-
ience,  to  standardize  the  diagnosis  of  ACOS  and  outline
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Table  1  Main  definitions  and  diagnostic  criteria  proposed.
Diagnostic criteria/
references
7  (Gibson
PG
32  (Hardin
M)
62 (Soler-
Cataluna
JJ)
63 (Czech
guidelines)
64
(Louie S)
65
(Izquierdo-
Alonso
JL)
6 (Joint
project of
GOLD and
GINA)
18
(Menezes
AM)
66  (Finish
Guide-
lines)
60
(Alshabanat A)
36 (Sin
DD)
46  (Cosio
BG)
Clinical criteria
No. of similar
characteristics of
asthma and COPD
X X
Simultaneously
diagnosis of asthma
and COPD
X X
COPD  and diagnosis or
symptoms of asthma
before age 40
X X X (M)
COPD  with previous
diagnosis of asthma
X (M) X (M) X X (M) X (M)
Bronchodilation test
Very positive response
(>400 mL and >15%
FEV1) in COPD
patients
X (M) X (M) X (M) X (M)
Very  positive response
(>400 mL FEV1)
X (M)
Positive  response
(>200 mL and >12%
FEV1) in COPD
patients
X (m) R X (m) X X (m) R X (m) 2R X (m) 2R
Positive  response
(≥15% FEV1 or ≥12%
and 200 mL FEV1)
X
Eosinophilia
Peripheral, in COPD
patients
X (m) X (m)
In  sputum, in COPD
patients
X (M) X (M) X (M)
Other
↑Total  IgE or previous
history of atopy
+COPD
X (m) X (m) X X (m) X X (m) X (m)
↑FENO  + COPD X (M) X (M)
Bronchial hyperre-
sponsiveness + DPOC
X (M) X
Evolution of PEF
typical of
asthma/PEF
variability + COPD
X (m) X
Age  ≥ 40 years X
X, indicates the references that include the criteria; M, considered a major criterion; m, considered a minor criterion; R, in repeated assessments; 2R, in at least two assessments.
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n  approach  strategy  for  this  group  of  patients,  for  whom
andomized  controlled  clinical  trials  (RCTs)  are  still  missing.
Proposed  recommendation:  the  diagnosis  of  ACOS
hould  be  considered  in  the  concomitant  presence  of:
)  simultaneous  clinical  manifestations  characteristic  of
both  asthma  and  COPD
)  persistent  airway  obstruction,  defined  as  post-
bronchodilator  FEV1/FVC  <  0.7,  evaluated  in  a  period  of
clinical  stability
)  positive  response  in  bronchodilator  test,  defined  by  an
increase  in  the  value  of  FEV1 of  ≥200  mL  and  ≥12%  from
baseline
)  current  or  past  history  of  smoking  or  exposure  to  biomass
combustion
As  aspects  that  are  usually  present  in  this  group  of
atients  and  that  can  be  taken  into  account  in  the  diag-
ostic  consideration,  we  highlight  peripheral  eosinophilia
>300  eosinophils/L or  >5%  of  leukocytes)  and  previous  his-
ory  of  atopy.  In  annex  1,  a  representation  of  the  proposed
lgorithm  is  presented.
revalence
iews  on  the  prevalence  of  ACOS  vary  greatly  among  the
ublished  studies,  reflecting  the  different  diagnostic  crite-
ia  applied  in  each,  as  well  as  the  different  populations
nalyzed.68--76
In  asthmatic  patients,  prevalence  of  ACOS  has  been
eported  as  ranging  between  13  and  30%.22,77--79 However,
hen  broader  criteria  are  used  and  subpopulations  of  older
atients  are  analyzed,  the  prevalence  recorded  is  higher;
or  example,  in  a  subgroup  of  asthmatic  patients  older  than
5  years,  a  prevalence  of  61%  was  found.22
Within  the  group  of  patients  with  COPD,  the  estimated
revalence  of  ACOS  is  also  varies  greatly  across  studies,  with
alues  ranging  between  9%  and  55%.18,65,77,80--82
In  the  population-based  study  PLATINUM,  the  prevalence
f  ACOS  was  2%,  and  the  prevalence  of  asthma  and  COPD  was
%  and  12%,  respectively.18 In  other  similar  studies,  a  preva-
ence  of  ACOS  in  the  general  population  ranging  between
 and  5%  was  found,  with  increasing  prevalence  associated
ith  an  increase  of  the  age  group  being  analyzed.22,83
Due  to  lack  of  studies  to  date,  ACOS  prevalence  data
elating  to  Portugal  are  not  known
pproach
reatment
imilar  to  the  other  chronic  obstructive  pulmonary  diseases,
he  therapeutic  approach  to  ACOS  patients  always  starts
ith  a  risk  factor  exposure  control,  in  which  we  highlight
moking,  exposure  to  biomass,  allergens  exposure,  anti-
nfectious  prevention,  among  many  others.  It  is  important
o  have  a  clinical  based  approach,  balanced  with  the  pres-Please  cite  this  article  in  press  as:  Araúj
http://dx.doi.org/10.1016/j.rppnen.2016.11.005
nce  of  comorbidities  and  further  assessment  (lung  function,
osinophilia,  among  others).
In  terms  of  pharmacological  therapy,  the  clinical  evi-
ence  in  ACOS  is  limited,  because  the  majority  of  these
- PRESS
D.  Araújo  et  al.
atients  are  systematically  excluded  from  most  of  the  clin-
cal  COPD  and  asthma  pharmacological  clinical  trials.  Only
hree  studies  (one  with  the  use  of  LAMA84 and  the  other  two
ith  oral  corticosteroids85,86)  were  performed  specifically
n  this  group  of  patients.  The  majority  of  the  consen-
us  documents  points,  however,  towards  an  important  role
f  bronchodilators  with  LABA,  isolated  or  in  combination
ith  LAMA,  always  associated  with  ICS.6,63,66,87 The  use  of
CS/LABA  as  a  first  line  of  therapy  is  recommended  by  the
ajority  of  the  consensus.
The  use  of  LABA  alone  in  asthma  patients  has  been  asso-
iated  with  poor  disease  control,  increase  of  its  severity
nd  mortality,  and  therefore  its  use  is  contraindicated  in
sthma  patients.88 Although  this  fact  has  not  been  estab-
ished  in  ACOS,  the  majority  of  the  guidelines  extrapolate
his  consideration  into  this  group.
The  use  of  ICS  in  ACOS  patients  has  been  revealed  as
eneficial  when  compared  to  its  use  in  COPD,  resulting  in  an
mprovement  in  FEV1.89 The  ICS  dose  used  can  be  adjusted
o  each  patient,  depending  on  their  symptoms  and  smoking
abits.64,90,91
Triple  therapy  with  ICS/LABA/LAMA  has  shown  an  exacer-
ation  reduction  in  COPD  patients92 but  this  fact  has  yet  to
e  proven  in  ACOS.  However,  most  of  the  consensus  doc-
ments  consistently  point  to  the  use  of  this  approach  in
on-controlled  patients  with  ICS/LABA.
New  therapies  have  begun  to  be  studied  in  ACOS
atients,  such  as  the  use  of  the  monoclonal  antibody  anti-
gE,  omalizumab,  which  seems  to  show  promising  results
n  terms  of  symptomatic  improvement  and  exacerbations
eduction.93,94 Other  specific  therapies  focused  on  the  rel-
vant  role  of  eosinophils  (anti  IL-5,  anti  IL-13  and  anti
L-33  drugs),  treatments  regarding  the  neutrophilic  expres-
ion  (macrolides,  p38  mitogenactivated  protein  kinase
nhibitors,  anti  IL-1  and  anti  IL-17  antibodies,  phosphodie-
terase  4  inhibitors)  could  play  a significant  role  on  the
rognosis  of  ACOS  patients.95
As  referred  to  above,  the  appropriate  treatment  of  the
requent  comorbidities  present  in  these  patients  is  cru-
ial,  as  well  as  an  effective  vaccination  coverage  and  the
mplementation  of  a  pulmonary  rehabilitation  programme,
specially  in  patients  with  a  higher  COPD  burden,  which  in
ore  advanced  stages,  determines  the  prognosis  of  patients
ith  ACOS  characteristics.  Moreover,  it  is  necessary  to  ver-
fy  in  a  consistent  and  regular  way  the  inhalation  technique,
einforcing  the  importance  of  the  inhaled  therapy  adher-
nce.
Proposed  recommendations:
 ICS/LABA  as  first  line  therapy.  In  patients  which  are  not
controlled  or  whose  clinical  severity  justifies,  a  triple
therapy  with  ICS/LABA/LAMA  should  be  used.
 Non-pharmacological  therapy  such  as  pulmonary  rehabili-
tation  should  be  done  in  ACOS  patients  with  uncontrolled
symptomatology  (frequent  exacerbations).
 Comorbidities  treatment  should  be  optimized  for  a  bettero  D,  et  al.  Rev  Port  Pneumol.  2016.
control  of  the  lung  disease.
 Risk  factors  exposure  control  (smoking,  biomass,  allergens
exposure)  and  vaccination  coverage  (influenza  and  anti-
pneumococcal).
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Referral  and  follow-up
The  best  way  forward  for  these  patients  in  terms  of
health  care  is  still  not  completely  established,  however,
the  GINA  and  GOLD  recommendation  document  reveals
some  guidance  such  as:  ACOS  patients  should  be  referred
to  a  specialist  if  they  present  persistent  or  uncontrolled
symptoms  and/or  common  exacerbations,  if  there  is  a  diag-
nostic  uncertainty,  atypical  symptoms/signs,  or  important
comorbidities.6
Proposed  recommendations:
-  The  patient  with  ACOS  should  be  given  a specialized  hos-
pital  appointment  if  control  of  symptoms  has  not  been
achieved  or  if  there  is  a  diagnostic  uncertainty.  If  clini-
cal  stability  is  achieved  in  a  consistent  way,  the  patient’s
follow-up  can  be  performed  by  the  family  doctor.
-  The  frequency  of  the  follow-up  of  these  patients  is  going
to  depend  on  their  clinical  stability  and/or  severity.  How-
ever,  given  the  characteristics  shown  by  these  patients,
a  medical  observation  for  symptoms  control  on,  at  least,
a  twice  a  year  basis  is  recommended,  as  well  as  a  spiro-
metric  evaluation  with  a  bronchodilator  test  at  least  once
a  year.  To  help  the  assessment  of  symptoms  control,  the
mMRC  dyspnoea  scale  and,  especially,  in  patients  with
a  higher  asthmatic  component,  the  CARAT  questionnaire
(although  not  validated  in  ACOS)  should  be  used.
Conclusions
This  document  sets  forward  the  heterogeneity  of  diagnosis
that  still  exists  in  this  area,  which  underlines  its  importance
as  a  first  stage  in  the  examination  of  this  field.  It  seems  clear
there  is  a  group  of  patients  who  share  characteristics  that
cross  the  COPD  and  asthma  spectrum,  it  is  therefore  crucial
to  achieve  a  more  accurate  identification  of  these  patients,
enabling  a  more  effective  therapeutic  approach.  In  the
future  this  characterization  of  ACOS  patients  will  provide
for  the  development  of  national  prevalence  studies  and  the
evaluation  of  the  impact  of  different  pharmacological  and
non-pharmacological  therapies,  which  will  complement  our
knowledge  of  this  entity  and  optimize  treatment  strategies.
This  document  constitutes  a  first  step  towards  what  might
become  a  nationwide  Portuguese  consensus  in  relation  to
ACOS,  which  would  strengthen  the  medical  community’s
vision  on  this  subject.
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